BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

937 related articles for article (PubMed ID: 31791167)

  • 41. Reproductive outcomes after a single dose of gonadotropin-releasing hormone agonist compared with human chorionic gonadotropin for the induction of final oocyte maturation in hyper-responder women aged 35-40 years.
    Tannus S; Turki R; Cohen Y; Son WY; Shavit T; Dahan MH
    Fertil Steril; 2017 Jun; 107(6):1323-1328.e2. PubMed ID: 28501366
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Endometrial gene expression in the early luteal phase is impacted by mode of triggering final oocyte maturation in recFSH stimulated and GnRH antagonist co-treated IVF cycles.
    Humaidan P; Van Vaerenbergh I; Bourgain C; Alsbjerg B; Blockeel C; Schuit F; Van Lommel L; Devroey P; Fatemi H
    Hum Reprod; 2012 Nov; 27(11):3259-72. PubMed ID: 22930004
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Intranasal gonadotropin-releasing hormone agonist (GnRHa) for luteal-phase support following GnRHa triggering, a novel approach to avoid ovarian hyperstimulation syndrome in high responders.
    Bar-Hava I; Mizrachi Y; Karfunkel-Doron D; Omer Y; Sheena L; Carmon N; Ben-David G
    Fertil Steril; 2016 Aug; 106(2):330-3. PubMed ID: 27114332
    [TBL] [Abstract][Full Text] [Related]  

  • 44. GnRH agonist trigger with intensive luteal phase support vs. human chorionic gonadotropin trigger in high responders: an observational study reporting pregnancy outcomes and incidence of ovarian hyperstimulation syndrome.
    Christopoulos G; Vlismas A; Carby A; Lavery S; Trew G
    Hum Fertil (Camb); 2016 Sep; 19(3):199-206. PubMed ID: 27662416
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The freeze-all strategy versus agonist triggering with low-dose hCG for luteal phase support in IVF/ICSI for high responders: a randomized controlled trial.
    Santos-Ribeiro S; Mackens S; Popovic-Todorovic B; Racca A; Polyzos NP; Van Landuyt L; Drakopoulos P; de Vos M; Tournaye H; Blockeel C
    Hum Reprod; 2020 Dec; 35(12):2808-2818. PubMed ID: 32964939
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Ovarian hyperstimulation syndrome in the 21st century: the role of gonadotropin-releasing hormone agonist trigger and kisspeptin.
    Thomsen L; Humaidan P
    Curr Opin Obstet Gynecol; 2015 Jun; 27(3):210-4. PubMed ID: 25811256
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of dual trigger with combination GnRH agonist and hCG versus hCG alone trigger of oocyte maturation for normal ovarian responders.
    Zhou X; Guo P; Chen X; Ye D; Liu Y; Chen S
    Int J Gynaecol Obstet; 2018 Jun; 141(3):327-331. PubMed ID: 29388691
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dual trigger of final oocyte maturation in poor ovarian responders undergoing IVF/ICSI cycles.
    Zhang J; Wang Y; Mao X; Chen Q; Hong Q; Cai R; Zhang S; Kuang Y
    Reprod Biomed Online; 2017 Dec; 35(6):701-707. PubMed ID: 28993105
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Is oocyte maturation rate associated with triptorelin dose used for triggering final oocyte maturation in patients at high risk for severe ovarian hyperstimulation syndrome?
    Lainas GT; Lainas TG; Sfontouris IA; Chatzimeletiou K; Venetis CA; Bosdou JK; Tarlatzis BC; Grimbizis GF; Kolibianakis EM
    Hum Reprod; 2019 Sep; 34(9):1770-1777. PubMed ID: 31384921
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Maternal and neonatal outcomes after gonadotropin-releasing hormone agonist trigger for final oocyte maturation in patients undergoing in vitro fertilization.
    Budinetz TH; Mann JS; Griffin DW; Benadiva CA; Nulsen JC; Engmann LL
    Fertil Steril; 2014 Sep; 102(3):753-8. PubMed ID: 24954776
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Early luteal phase endocrine profile is affected by the mode of triggering final oocyte maturation and the luteal phase support used in recombinant follicle-stimulating hormone-gonadotropin-releasing hormone antagonist in vitro fertilization cycles.
    Fatemi HM; Polyzos NP; van Vaerenbergh I; Bourgain C; Blockeel C; Alsbjerg B; Papanikolaou EG; Humaidan P
    Fertil Steril; 2013 Sep; 100(3):742-7. PubMed ID: 23806846
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does an FSH surge at the time of hCG trigger improve IVF/ICSI outcomes? A randomized, double-blinded, placebo-controlled study.
    Qiu Q; Huang J; Li Y; Chen X; Lin H; Li L; Yang D; Wang W; Zhang Q
    Hum Reprod; 2020 Jun; 35(6):1411-1420. PubMed ID: 32383771
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Gonadotropin-releasing hormone agonist for ovulation trigger - OHSS prevention and use of modified luteal phase support for fresh embryo transfer.
    Castillo JC; Haahr T; Martínez-Moya M; Humaidan P
    Ups J Med Sci; 2020 May; 125(2):131-137. PubMed ID: 32366146
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effect of Dual Trigger In Vitro Fertilization and Intracytoplasmic Sperm Injection During the Gonadotropin-releasing Hormone-Antagonist Cycle on Final Oocyte Maturation and Cumulative Live Birth Rate in Women with Diminished Ovarian Reserve.
    Ren YM; Wang YB; Fu M; Zhang QX; Shen H; Han HJ; Gao FM
    Curr Med Sci; 2022 Oct; 42(5):1066-1070. PubMed ID: 35997911
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Individual luteolysis post GnRH-agonist-trigger in GnRH-antagonist protocols.
    Lawrenz B; Ruiz F; Engelmann N; Fatemi HM
    Gynecol Endocrinol; 2017 Apr; 33(4):261-264. PubMed ID: 28019139
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [GnRH agonist triggering in IVF and luteal phase support in women at risk of ovarian hyperstimulation syndrome].
    Guivarc'h-Levêque A; Jaffré F; Homer L; Moy L; Priou G; Colleu D; Denis I; Arvis P
    Gynecol Obstet Fertil; 2013 Sep; 41(9):511-4. PubMed ID: 23972925
    [TBL] [Abstract][Full Text] [Related]  

  • 57. GnRH agonist trigger for the induction of oocyte maturation in GnRH antagonist IVF cycles: a SWOT analysis.
    Engmann L; Benadiva C; Humaidan P
    Reprod Biomed Online; 2016 Mar; 32(3):274-85. PubMed ID: 26803205
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The prevention of ovarian hyperstimulation syndrome.
    Corbett S; Shmorgun D; Claman P; ;
    J Obstet Gynaecol Can; 2014 Nov; 36(11):1024-1033. PubMed ID: 25574681
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Substituting HCG with GnRH agonist to trigger final follicular maturation--a retrospective comparison of three different ovarian stimulation protocols.
    Orvieto R; Rabinson J; Meltzer S; Zohav E; Anteby E; Homburg R
    Reprod Biomed Online; 2006 Aug; 13(2):198-201. PubMed ID: 16895632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Hormonal profile in early luteal phase after triggering ovulation with gonadotropin-releasing hormone agonist in high-responder patients.
    Martazanova B; Mishieva N; Vedikhina I; Kirillova A; Korneeva I; Ivanets T; Abubakirov A; Sukhikh GT
    Front Endocrinol (Lausanne); 2022; 13():834627. PubMed ID: 36046787
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 47.